My Authors
Read all threads
A little history of Neratinib, approved this week in 2+ HER2 mBCA despite the fact it has massive diarrhea and no survival benefit when compared to lapatinib

Shown here from drug label
(0.88 (0.72, 1.07) p =2086)
In 2012, we knew that TDM-1 had improved OS over lapatinib- c in 1+ her2+ breast ca
In 2013, a trial was launched testing neratinib -c vs lapatinib c in 2+ her2+ breast ca

What percent got TDM-1 prior to enrollment?

What percent got pertuzumab?

What percent already got lapatinib?

reply if you know the answers
And stay tuned to next @Plenary_Session
Missing some Tweet in this thread? You can try to force a refresh.

Enjoying this thread?

Keep Current with Vinay Prasad

Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

Twitter may remove this content at anytime, convert it as a PDF, save and print for later use!

Try unrolling a thread yourself!

how to unroll video

1) Follow Thread Reader App on Twitter so you can easily mention us!

2) Go to a Twitter thread (series of Tweets by the same owner) and mention us with a keyword "unroll" @threadreaderapp unroll

You can practice here first or read more on our help page!

Follow Us on Twitter!

Did Thread Reader help you today?

Support us! We are indie developers!

This site is made by just three indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3.00/month or $30.00/year) and get exclusive features!

Become Premium

Too expensive? Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal Become our Patreon

Thank you for your support!